LISAvienna: Open Calls and Deadlines to remember

Lean more about funding and support opportunities for the life sciences in Vienna.

In the Vienna area, research and companies profit from one of the most progressive funding landscapes in Europe. Please find information on some open calls and deadlines below.

December 17: Cutoff date, Horizon 2020 dedicated SME Instrument – phase 1 and phase 2, 2014; focus: clinical research for the validation of biomarkers and/or diagnostic medical devices >> Next cutoff date scheduled for March 18 >>

December 31: Cutoff date, Cooperation Program at Vienna Business Agency >>

January 20: Ludwig Boltzmann Society closes call for new Institutes for Health Sciences >>

January 21: Cutoff date, OeNB Anniversary Fund >>

January 30: 10th EuroTransBio joint call for transnational projects closes >>

January 31: Rudolf Sallinger Fonds closes: 20,000 Euros for the best research-based commercial plan >>

February 5: Deadline of Vienna Business Agency's Call for Shared Research Facilities >>

February 13: Deadline for submitting business plans to aws Best of Biotech >>

February 18: ERA-NET “ERARE-3”, expected deadline for pre-proposals for European research projects on rare diseases >>

February 23: Deadline for short proposals at ERA-IB, 6th Joint Call EuroTransBio Partners; focus: industrial biotechnology >>

February 24/April 21: Horizon 2020 "Health, demographic change and wellbeing" deadline >>

March 12: Deadline of Vienna Business Agency's “Pro Industry“ Call >>

March 18: Cutoff date, Horizon 2020 dedicated SME Instrument >>

March 23: Deadline for “Benefit – demographic change“ at FFG >>

March 26: Horizon 2020 “Biotechnology“ deadline >>

March 26: Horizon 2020 “Nanotechnologies, advanced materials and production“ deadline >>

Pre-announcements:
- Ambient Assisted Living Joint Programme: “Living active and independently at home“ call >>
- FFG Bridge >>

This list is not exhaustive. Please also check out www.foerderkompass.at or www.wko.at/foerderungen and contact our technology experts Jürgen Fuchs (Biotech/Pharma) and Martin Mayer (Medtech) for an individual account on funding and support opportunities.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.